CD19 and acute lymphoblastic leukemia: For instance, given the substantial improvement in overall survival by the mAb anti-CD20 rituximab in ALL patients with significant CD20 expression (≥20%), the implementation of CD19 mAb, potentially reaching a broader spectrum of patients, is a reasonable strategy [123].